AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ANGO · NASDAQ · Medical - Instruments & Supplies

AngioDynamics (ANGO)

Builds vascular and oncology devices around atherectomy, thrombectomy, ablation, and access lines.

$15.67

After hours−0.01 (−0.03%)

At close$15.68(+1.65%)

In millions of USD, except per-share figures

In millions	Q1 FY24Aug 2023	Q2 FY24Nov 2023	Q3 FY24Feb 2024	Q4 FY24May 2024	Q1 FY25Aug 2024	Q2 FY25Nov 2024	Q3 FY25Feb 2025	Q4 FY25May 2025	Q1 FY26Aug 2025	Q2 FY26Nov 2025	Q3 FY26Feb 2026	Q4 FY26May 2026
Revenue	79	79	75	71	67	73	72	80	76	79	78	87
Cost of revenue	39	39	39	32	31	33	33	38	34	37	37	37
Gross profit	40	40	36	39	37	40	39	42	42	42	41	49
	5	53	236	53	50	51	49	48	53	45	48	70
Research & development	8	9	8	7	6	6	7	7	6	8	7	8
	38	35	36	35	37	36	36	37	41	37	38	41
Selling & marketing	27	25	25	25	26	26	26	26	28	27	27	31
General & administrative	11	9	11	10	11	10	10	10	13	10	11	10
Other expenses	−41	10	192	11	7	9	6	5	5	0	3	20
Operating income	35	−13	−200	−14	−13	−11	−10	−6	−11	−2	−6	−20
	0	1	0	0	0	0	6	0	0	−4	−2	9
Interest income	0	1	0	1	1	0	0	0	0	0	0	0
Interest expense	0	0	0	0	0	0	0	0	0	0	0	0
Other non-operating income	45	−6	−188	−9	−4	−6	−3	−2	0	4	2	−9
Income before tax	35	−13	−200	−14	−13	−11	−4	−6	−11	−6	−8	−11
Income tax expense	−11	16	−12	−1	0	0	0	0	0	0	0	0
Net income from continuing operations	46	−29	−188	−13	−13	−11	−4	−6	−11	−6	−8	−11
Net income	46	−29	−188	−13	−13	−11	−4	−6	−11	−6	−8	−11
EPS, basic	$1.15	−$0.72	−$4.67	−$0.33	−$0.31	−$0.26	−$0.11	−$0.15	−$0.26	−$0.15	−$0.19	−$0.28
EPS, diluted	$1.15	−$0.72	−$4.67	−$0.33	−$0.31	−$0.26	−$0.11	−$0.15	−$0.26	−$0.15	−$0.19	−$0.28
Weighted average shares, basic	40	40	40	40	41	41	41	41	41	41	42	42
Weighted average shares, diluted	40	40	40	40	41	41	41	41	41	41	42	42
EBITDA	−3	0	−4	1	−2	2	0	2	−5	0	−2	−28
Depreciation & amortization	7	7	8	7	7	7	6	6	6	6	6	−17
EBIT	−10	−7	−12	−6	−9	−5	−7	−4	−11	−6	−8	−11